LB Pharmaceuticals Inc appointed Susan G. Kozauer, M.D., as Chief Medical Officer effective September 14, 2026. Dr. Kozauer brings over two decades of neuropsychiatric drug development experience, previously serving as Senior Vice President and Head of Clinical Development at Centessa Pharmaceuticals and Vice President in Clinical Development at Intra-Cellular Therapies. Her compensation includes a $515,000 annual base salary, a target bonus equal to 40% of her base, and a $150,000 one-time sign-on bonus payable over two years subject to continued employment. She will receive an option to purchase 200,000 shares of common stock vesting over four years as an inducement grant under Nasdaq Listing Rule 5635(c)(4). The company is a neuromedicines firm developing therapies for underserved brain disorders.

LB Pharmaceuticals Inc announced the appointment of Joseph M. Miller as its new Chief Financial Officer, effective September 2, 2026. Mr. Miller brings over two decades of experience in public and private biotech firms, most recently serving as CFO of Aurinia Pharmaceuticals Inc. His employment agreement includes an annual base salary of $530,000, a target bonus equal to 40% of his salary, and a grant of options to purchase 200,000 shares of common stock vesting over four years. The appointment coincides with the company's approach toward pivotal NOVA-2 clinical trial results for its lead candidate LB-102 and preparations for potential commercialization in schizophrenia. LB Pharmaceuticals is a neuromedicines company developing therapies for underserved brain disorders.

LB Pharmaceuticals Inc reported a net loss of $51.6 million for the quarter ended June 30, 2026, driven by a surge in research and development expenses to $44.1 million as it advances its lead asset, LB-102. The company announced that enrollment in the pivotal Phase 3 NOVA-2 trial for schizophrenia is ahead of schedule, projecting topline data readout in the first half of 2027, with a pre-NDA meeting planned for the second half of 2027. Additionally, LB Pharmaceuticals completed a $150 million private placement in July 2026 to fund pipeline expansion into new neuropsychiatric indications and general corporate purposes. As of June 30, 2026, the company held $327.8 million in cash, cash equivalents, and marketable securities, which is expected to support operations beyond the second quarter of 2029. The company also appointed Christopher Zergebel as Senior Vice President, Clinical Operations. LB Pharmaceuticals operates in the biotechnology industry, focusing on developing neuromedicines for underserved brain diseases.

LB Pharmaceuticals Inc entered into a Securities Purchase Agreement on July 28, 2026, to raise approximately $150 million in gross proceeds through a private placement. The company sold 3,577,560 shares of common stock at $34.94 per share and pre-funded warrants for up to 715,513 additional shares at $34.9399 each. Proceeds are intended to fund pipeline expansion for its lead candidate LB-102 into new indications, including negative symptoms of schizophrenia and Alzheimer’s disease agitation/psychosis, as well as working capital. The transaction closed on July 30, 2026, with Leerink Partners LLC and Piper Sandler & Co. acting as placement agents. LB Pharmaceuticals is a neuromedicines company developing therapies for underserved brain diseases.

LB Pharmaceuticals Inc announced an accelerated timeline for topline results from its Phase 3 NOVA-2 clinical trial of LB-102 for schizophrenia, now expecting to report results in the first half of 2027 instead of the second half of 2027. The company also expects to schedule a pre-NDA meeting with the FDA in the second half of 2027. LB Pharmaceuticals is a neuromedicines company focused on developing therapies for brain diseases.

Anna Eramo, M.D., resigned as Chief Medical Officer on June 8, 2026, effective June 15, 2026, for personal reasons. She will serve as a full-time consultant through September 15, 2026. Under a separation agreement, if she completes the consulting period, she will receive her base salary monthly until June 15, 2027, a prorated 2026 target annual bonus, and the acceleration of 66,143 unvested stock options on September 15, 2026. The company will also reimburse COBRA healthcare premiums for up to 12 months. The company stated the departure is unrelated to clinical operations and does not expect a material impact on clinical development activities. LB Pharmaceuticals Inc is a biopharmaceutical company focused on the development of clinical-stage product candidates.